Program
bimekizumab
Also written as “Bimekizumab”, “Bimekizumab regimen 1 iv” and “Bimekizumab regimen 2 iv”.
Its studies are mostly in Arthritis, Psoriatic · Psoriasis · Hidradenitis Suppurativa · Spondylitis, Ankylosing · Axial Spondyloarthritis, led by UCB.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCB | 437 open or running | phase 3since Dec 7, 2017 | May 15, 2014 | Dec 21, 2026phase 3 · NCT06921850 |
Also a collaborator on its studies: parexel and comac-medical.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 29 studies since May 15, 2014.
- Jan 18, 2021Phase 2 study in PsoriasisNCT04718896 · 41 enrolled · United States, Canada, Germany and more
- May 20, 2021Phase 3 study in Hidradenitis SuppurativaNCT04901195 · 658 enrolled · United States, Australia, Belgium and more
- Aug 20, 2021Phase 3 study in Moderate to Severe Plaque PsoriasisNCT05020249 · 47 enrolled · Korea, Republic of
- Aug 25, 2021Phase 1 study in Healthy VolunteersNCT05028127 · 12 enrolled · United Kingdom
- Mar 14, 2022Phase 1 study in Healthy Study ParticipantsNCT05292131 · 121 enrolled · United States, Germany
- Aug 21, 2023Phase 3 study in PsoriasisNCT06011733 · 133 enrolled · China
- May 2, 2024Phase 3 study in PsoriasisNCT06425549 · 176 enrolled · United States, Belgium, Canada and more
- Jul 9, 2024Phase 3 study in Arthritis, PsoriaticNCT06506916 · 89 enrolled · United States, Germany, Poland
- Sep 30, 2024Phase 3 study in Arthritis, PsoriaticNCT06624228 · 553 enrolled · United States, Australia, Bulgaria and more
- Oct 30, 2024Phase 3 study in Arthritis, JuvenileNCT06668181 · 40 planned · Canada, France, Germany and more
- Mar 15, 2025Phase 1 study in Arthritis, PsoriaticNCT06888193 · 20 planned · United States, Canada, Germany and more
- Apr 3, 2025Phase 3 study in Hidradenitis SuppurativaNCT06921850 · 43 enrolled · United States, Germany, Poland
- Oct 17, 2025Phase 3 study in PsoriasisNCT07219420 · 320 planned · United States, Canada, China and more
- Dec 4, 2025Phase 1 study in Arthritis, PsoriaticNCT07290036 · 392 planned · United States, Bulgaria, Czechia and more
Ahead
- Dec 21, 2026Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06921850
- Mar 9, 2027Primary completion: phase 3 study in Arthritis, PsoriaticNCT06506916
- Dec 27, 2027Primary completion: phase 3 study in PsoriasisNCT07219420
- Dec 31, 2027Primary completion: phase 1 study in Arthritis, PsoriaticNCT06888193
TargetBeta
“Interleukin 17A inhibitor; Interleukin-17F inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sonelokimabrule | moonlake-immunotherapeutics-ag | phase 3 | 12 |
Studies
All 43 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07290036Arthritis, Psoriatic · United States, Bulgaria, Czechia and more | 1 | Recruiting | May 18, 2028 | 392 |
| NCT07219420Psoriasis · United States, Canada, China and more | 3 | Recruiting | Dec 27, 2027 | 320 |
| NCT06921850Hidradenitis Suppurativa · United States, Germany, Poland | 3 | Active, not recruiting | Dec 21, 2026 | 43 |
| NCT06888193Arthritis, Psoriatic · United States, Canada, Germany and more | 1 | Recruiting | Dec 31, 2027 | 20 |
| NCT06668181Arthritis, Juvenile · Canada, France, Germany and more | 3 | Recruiting | Apr 12, 2028 | 40 |
| NCT06624228Arthritis, Psoriatic · United States, Australia, Bulgaria and more | 3 | Completed | Feb 6, 2026 | 553 |
| NCT06506916Arthritis, Psoriatic · United States, Germany, Poland | 3 | Active, not recruiting | Mar 9, 2027 | 89 |
| NCT06425549Psoriasis · United States, Belgium, Canada and more | 3 | Active, not recruiting | Aug 21, 2028 | 176 |
| NCT06011733Psoriasis · China | 3 | Completed | Feb 5, 2025 | 133 |
| NCT05292131Healthy Study Participants · United States, Germany | 1 | Completed | Jan 9, 2023 | 121 |
| NCT05028127Healthy Volunteers · United Kingdom | 1 | Completed | Jun 17, 2016 | 12 |
| NCT05020249Moderate to Severe Plaque Psoriasis · Korea, Republic of | 3 | Completed | Sep 5, 2022 | 47 |
| NCT04901195Hidradenitis Suppurativa · United States, Australia, Belgium and more | 3 | Completed | Jul 22, 2026 | 658 |
| NCT04718896Psoriasis · United States, Canada, Germany and more | 2 | Completed | Mar 12, 2025 | 41 |
| NCT04436640Axial Spondyloarthritis · United States, Belgium, Bulgaria and more | 3 | Completed | Aug 9, 2026 | 508 |
| NCT04255862Healthy Study Participants · Germany | 1 | Terminated | Apr 26, 2021 | 71 |
| NCT04242498Hidradenitis Suppurativa · United States, Australia, Bulgaria and more | 3 | Completed | Nov 9, 2021 | 509 |
| NCT04242446Hidradenitis Suppurativa · United States, Australia, Belgium and more | 3 | Completed | Apr 7, 2022 | 505 |
| NCT04109976Arthritis, Psoriatic · United States, Czechia, Germany and more | 3 | Completed | Nov 5, 2020 | 214 |
| NCT04009499Arthritis, Psoriatic · United States, Australia, Belgium and more | 3 | Completed | May 26, 2026 | 1,131 |
| NCT03928743Spondylitis, Ankylosing · United States, Belgium, Bulgaria and more | 3 | Completed | Sep 3, 2021 | 332 |
| NCT03928704Axial Spondyloarthritis · United States, Belgium, Bulgaria and more | 3 | Completed | Jun 29, 2022 | 274 |
| NCT03895385Healthy Volunteers · United States | 1 | Completed | Oct 4, 2019 | 56 |
| NCT03895203Arthritis, Psoriatic · United States, Australia, Belgium and more | 3 | Completed | Aug 17, 2021 | 852 |
| NCT03896581Arthritis, Psoriatic · United States, Australia, Canada and more | 3 | Completed | Dec 8, 2021 | 400 |
| NCT03766685Psoriasis · United States, Canada | 3 | Completed | Jul 14, 2020 | 172 |
| NCT03707717Healthy Volunteers · United States, Germany | 1 | Completed | Jun 5, 2019 | 189 |
| NCT03598790Psoriasis · United States, Australia, Belgium and more | 3 | Completed | Nov 14, 2023 | 1,353 |
| NCT03412747Psoriasis · United States, Australia, Canada and more | 3 | Completed | Feb 7, 2019 | 478 |
| NCT03410992Arthritis, Psoriatic · United States, Australia, Canada and more | 3 | Completed | Dec 28, 2018 | 435 |
| NCT03370133Arthritis, Psoriatic · United States, Australia, Belgium and more | 3 | Completed | Jan 8, 2019 | 567 |
| NCT03355573Spondylitis, Ankylosing · United States, Bulgaria, Canada and more | 2 | Completed | Oct 19, 2022 | 255 |
| NCT03347110Arthritis, Psoriatic · United States, Czechia, Germany and more | 2 | Completed | Oct 29, 2020 | 184 |
| NCT03248531Hidradenitis Suppurativa · United States, Australia, Belgium and more | 2 | Completed | Nov 23, 2018 | 90 |
| NCT03230292Psoriasis · United States, Australia, Canada and more | 2 | Completed | Mar 6, 2019 | 43 |
| NCT03215277Spondylitis, Ankylosing · United States, Czechia, Germany and more | 2 | Completed | May 25, 2020 | 76 |
| NCT03025542Psoriasis · United States, Australia, Canada and more | 2 | Completed | Dec 11, 2017 | 49 |
| NCT03010527Psoriasis · United States, Canada, Czechia and more | 2 | Completed | Sep 25, 2018 | 217 |
| NCT02969525Arthritis, Psoriatic · United States, Czechia, Germany and more | 2 | Completed | Nov 2017 | 206 |
| NCT02963506Spondylitis, Ankylosing · United States, Bulgaria, Canada and more | 2 | Completed | Oct 2017 | 303 |
| NCT02905006Psoriasis · United States, Canada, Czechia and more | 2 | Completed | Jun 2017 | 250 |
| NCT02529956Psoriasis · United Kingdom | 1 | Completed | Jan 2014 | 39 |
| NCT02141763Arthritis, Psoriatic · Bulgaria, Moldova, Republic of, United Kingdom | 1 | Completed | Aug 2015 | 53 |
How it is read
Names in the registry
- “Bimekizumab”, 35 entries
- “bimekizumab”, 5 entries
- “Bimekizumab regimen 1 iv”, 1 entry
- “Bimekizumab regimen 2 iv”, 1 entry
- “UCB4940 40 mg”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Psoriatic, 13 studies
- Psoriasis, 13 studies
- Hidradenitis Suppurativa, 5 studies
- Spondylitis, Ankylosing, 4 studies
- Axial Spondyloarthritis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.